Amvuttra

vutrisiran

Approval

ApplicationNDA 215515
Approval dateJun 13, 2022
Approval year2022
SponsorAlnylam Pharms INC

FDA-approved use

To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Amvuttra: